Theriva Holders Approve 500M Authorized Shares and 16.2M Warrant-Share Issuance
TOVX is trading near its 52-week low of $0.136 (5.9% above the low) on light trading volume (0.2× avg).
Summary
Theriva stockholders approved raising authorized common stock to 500,000,000 shares and ratified issuance of up to 16,184,560 warrant shares from the 2025 private placement. No new shares have been sold — this is authorization, not execution.
Key Events · Financing and Capital Events · TOVX
-
Authorized Shares Raised to 500 Million
Stockholders approved a charter amendment permitting authorized common stock of 500,000,000 shares, at the Board's discretion, versus 45,892,688 shares outstanding as of the October 9, 2026 record date.
-
Warrant Share Issuance Ratified
Up to 16,184,560 shares issuable on exercise of warrants from the October 17, 2025 private placement were approved, 2,804,211 for versus 2,516,522 against, with 11,373,054 broker non-votes.
-
Dilution Capacity, Not Yet Used
The charter amendment is authorization only — no shares have been issued under it, and the Board may elect not to file the amendment despite stockholder approval.
-
Vote Split on Dilution
Proposal 1 passed 10,798,374 to 5,790,533 with 165,316 abstentions; 16,754,223 shares, about 36.5% of the record-date count, were represented at the meeting.
Analysis · TOVX · Life Sciences
Shareholders have cleared the way for a far larger share count: authorized common stock can rise to 500,000,000 shares at the Board's discretion, against 45,892,688 outstanding on the October 9 record date. That leaves roughly 454 million shares of headroom — enormous relative to the current count — and it arrives while the company carries substantial doubt about its ability to continue as a going concern, with cash runway only into Q1 2027. Practically, Theriva now has the authorized capacity to raise equity or settle warrant obligations without another shareholder vote, making future dilution far easier to execute. Approval of the warrant proposal (up to 16,184,560 shares from the October 17, 2025 private placement) came by a much narrower margin, with 11.4 million broker non-votes, so the shareholder base is split on dilution. Note that the charter amendment is permission only — no shares have been issued under it, and the Board may elect not to file it at all.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TOVX was trading at $0.14 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.6M. The 52-week trading range was $0.14 to $0.49. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.